We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Herpes Simplex Virus Molecular Test Receives US FDA Clearance

By LabMedica International staff writers
Posted on 02 Mar 2015
A leading developer of multiplex polymerase chain reaction technology has announced that its herpes simplex virus (HSV) types 1 and 2 assay has been granted 510 (k) market clearance. More...


The tests are based on its breakthrough technology that allows simultaneous detection and quantification of multiple targets in a single fluorescence channel, without melting curve analysis and the tests are the most comprehensive and cost-effective multiplexed polymerase chain reaction (PCR) molecular assays for infectious disease in the industry.

The US Food and Drug Administration (FDA, Silver Springs, MD, USA) has granted the market clearance for the high multiplex real-time quantitative PCR known as TOCE technology, that enables confirmation of multiple (five or more) target genetic detection and genetic variation. TOCE can implement qualitative test that analyzes multiple clinical samples and quantitative analysis bases on Cyclic Catcher Melting Temperature Analysis (cyclic-CMTA).

The company producing the approved HSV types 1 and 2 assay is Seegene (Seoul, Republic of Korea) that uses the Allplex tests which are based on its breakthrough MuDT technology. This powerful technology is capable of simultaneous quantification and detection/discrimination of multiple targets in a single channel without additional melting curve analysis after amplification step. It satisfies the growing demands for both high multiplexing and quantification in a single assay by overcoming the current technology barrier of “one channel, only one cycle threshold (Ct).” MuDT technology opens a new chapter of PCR-based molecular diagnostics to deliver a more comprehensive and actionable diagnostic information.

Jong-Yoon Chun, PhD, founder, CTO and CEO of Seegene, said, “This is an important milestone in support of our planned entry into the USA, the largest molecular diagnostic market in the world. After more than 10 years of extensive efforts to continually develop and commercialize novel technologies to surpass the capabilities of real-time PCR, we successfully invented MuDT technology, an ultimate multiplex real-time PCR technology that marks a new era in the molecular diagnostics industry. Through the US FDA approval, Seegene now intends to actively enhance its leadership in the multiplex real-time PCR diagnostic testing market.”

Related Links:
US Food and Drug Administration 
Seegene 



New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Human Estradiol Assay
Human Estradiol CLIA Kit
New
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The ONC IN-CYT platform leverages cross indication biomarker cyto-signatures (Photo courtesy of OraLiva)

AI-Powered Cytology Tool Detects Early Signs of Oral Cancer

Each year, 54,000 Americans are diagnosed with oral cancer, yet only 28% of cases are identified at an early stage, when the five-year survival rate exceeds 85%. Most diagnoses occur in later stages, when... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: PD-1 protein blockade is the standard treatment for advanced melanoma among the different types of immunotherapy (Photo courtesy of 123RF)

Precision Tool Predicts Immunotherapy Treatment Failure in Melanoma Patients

Melanoma, though accounting for only about 4% of skin tumors, is the deadliest form of skin cancer due to its high potential to metastasize. While immunotherapy, especially PD-1 protein blockade, has revolutionized... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.